Relationship between pimavanserin exposure and psychosis relapse in patients with dementia-related psychosis: clinical results and modeling analysis from the phase 3 HARMONY study

Conference: American College of Neuropsychopharmacology

Dementia-related psychosis impacts more than 2.4 million patients;1-5 however, there are no US FDA-approved therapies. Pimavanserin is being investigated for the treatment of hallucinations and delusions associated with dementia-related psychosis. Exposure–response (E–R) analyses to assess the relationship between drug exposure and efficacy and/or safety are increasingly considered an integral part of clinical drug development.